There are 2789 resources available
327P - Predictors of progression-free survival in patients with metastatic breast cancer receiving palbociclib with letrozole
Presenter: Roya Behrouzi
Session: ePoster Display
328TiP - Phase III study of trastuzumab deruxtecan (T-DXd) with or without pertuzumab vs a taxane, trastuzumab and pertuzumab in first-line (1L), human epidermal growth factor receptor 2–positive (HER2+) metastatic breast cancer (mBC): DESTINY-Breast09
Presenter: Sara Tolaney
Session: ePoster Display
330TiP - Trastuzumab deruxtecan (T-DXd; DS-8201) in HER2-positive (HER2+) and HER2-low expressing (HER-LE) metastatic breast cancer (MBC) with brain metastases (BM) and/or leptomeningeal carcinomatosis (LMC): DEBBRAH
Presenter: Marta Vaz Batista
Session: ePoster Display
331TiP - HER2CLIMB-04: Phase II trial of tucatinib + trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases
Presenter: Lisa Carey
Session: ePoster Display
333TiP - AMEERA-1: Phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with alpelisib in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2–) PIK3CA-mutated advanced breast cancer
Presenter: Mario Campone
Session: ePoster Display
334TiP - A phase I trial of niraparib plus anlotinib in advanced solid tumors with homologous recombination repair (HRR) gene mutations
Presenter: Jiayang Zhang
Session: ePoster Display
335TiP - Open-label, multinational, multicenter, phase IIIb/IV study of trastuzumab deruxtecan (T-DXd) in patients with or without baseline brain metastasis with previously treated advanced/metastatic human epidermal growth factor receptor 2–positive breast cancer (HER2+ BC): DESTINY-Breast12
Presenter: Nancy Lin
Session: ePoster Display
336TiP - Ipatasertib plus non-taxane chemotherapy for metastatic triple-negative breast cancer (TNBC): Pathfinder trial
Presenter: Antonio Llombart Cussac
Session: ePoster Display